ClinicalTrials.gg
RecruitingNCT05183646ACTION3Updated Feb 3, 2026

A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB

A Phase 3 interventional study of DMX-200 and Placebo in FSGS, sponsored by Dimerix Bioscience Pty Ltd. Recruiting at 220 sites in 21 countries. Open to participants aged 12 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-03.

Sponsored by Dimerix Bioscience Pty Ltd · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
286
Allocation
Randomized
Ages
12 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States — 18 open to participants now, 21 under way, 2 of them phase 3. Glomerulosclerosis, Focal Segmental · United States.

Planned enrollment
3rd of 56
286 · median 30
Started
2022
with 7 others
Phase 3
5 of 69
2 open now
Primary completion
2029-12
later than 14 of 20 live
Registered
51st of 69
by date

Among the 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States, this one is the 3rd largest by planned enrollment of the 56 interventional ones that give a count, is one of 8 that started in 2022, is one of 5 in phase 3, reaches primary completion later than 14 of the 20 other live ones, and was the 51st registered.

Glomerulosclerosis, Focal Segmental

106 studies on the registry are indexed under Glomerulosclerosis, Focal Segmental; 34 are open to participants now.

Browse Glomerulosclerosis, Focal Segmental studies →

Open to participants now

18 of the 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Glomerulosclerosis, Focal Segmental studies recruiting now, 11 (35%) set no upper age limit and 13 (42%) stop at 75 or younger; 23 take children under 18; 2 take healthy volunteers.

This study: 12 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States, or all of them as a file.
02

Study summary

DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflammatory chemokine environment of chronic disease. The purpose of this pivotal randomized double-blind study is to investigate the efficacy and safety of DMX-200 120 mg twice daily (BID) compared with placebo over a treatment period of 104 weeks in adult patients with FSGS who are being treated with an ARB. Given the rarity of the disease and the similarities between adults and pediatric patients with FSGS, Dimerix will also investigate the efficacy and safety of DMX 200 in adolescents aged 12 to 17 years. The double-blind period will be followed by an open-label extension (OLE) which aims to assess the long-term efficacy and safety of DMX 200 for up to 2 additional years.

Read the detailed description

This is a pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with FSGS. The duration of the double-blind period per patient is estimated to be maximum of 122 weeks, a Screening and Qualification period of between 6 and 14 weeks (including a 4 week period to complete the assessments required for Screening, Titration (if required, up to 4 weeks) and, 6-weeks of Stabilization, a 104-week Treatment period, and up to a 4-week off-treatment Follow-up period. The treatment duration of the OLE period per patient is estimated to be a minimum of 104 weeks (2 years) with a 4-week off-treatment Follow-up period. The total study duration (double-blind period and OLE combined) is currently estimated to be a minimum of 230 weeks.

03

Conditions studied

  • FSGS

Keywords

  • fsgs
  • focal segmental glomerulosclerosis
  • kidney disease
04

Who can participate

Ages eligible
12 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

DOUBLE BLIND PERIOD

Inclusion Criteria:

  1. Patients must be 12 to 80 years old
  2. A diagnosis of primary FSGS, genetic FSGS, or FSGS of undetermined cause. Confirmed by kidney within 7 years of screening
  3. Must be either receiving an ARB at the maximal tolerated dose or willing to transition
  4. If taking , the dosage must be stable for ≥4 weeks prior to Screening and during Stabilization
  5. If taking aldosterone inhibitors, mineralocorticoid receptor antagonists, direct renin inhibitors, sodium-glucose co-transporter-2 (SGLT2) inhibitors, or endothelin receptor antagonists (ERAs, including dual antagonists), the dose and regimen must be stable for ≥12 weeks prior to Screening and during Stabilization
  6. Urine PCR >1.5 g/g (>169.5 mg/mmol) or 24-hour total protein >1.5 g/day based on 24-hour urine collection during Screening.
  7. Estimated ≥25 and ≤120 mL/min/1.73 m2 at Screening for adults \& eGFR ≥25mL/min/1.73 m2 for adolescent patients (\<18 years)
  8. Seated blood pressure ≤160/100 mm Hg (mean of 3 values) (patients ≥18 years of age) or between the 5th and 95th percentile for age, sex, and height (patients \<18 years of age) at Screening
  9. Body weight ≥35 kg (all patients) AND a (BMI) ≤40 kg/m2 (patients ≥18 years of age) or between the 5th and 98th percentile for age and sex (patients \<18 years of age) at Screening.
  10. A female patient is eligible to participate if she is not pregnant or planning to become pregnant during the study, not breastfeeding, and at least one of the following conditions applies:

    1. Is not of
    2. If of childbearing potential and beginning at menarche, agrees to use a highly effective method of consistently during the treatment period.
  11. A male patient with a female partner of childbearing potential is eligible to participate if he agrees to use acceptable contraception
  12. A patient or parent/legal guardian (as appropriate) who is capable of giving signed , and where required, the patient is capable of providing assent.

Exclusion Criteria:

  1. Has FSGS secondary to another condition.
  2. Patients with nephrotic syndrome (>3.5 g/day proteinuria and serum albumin \<30 g/L) who have not previously been treated with standard of care FSGS-directed therapies (including steroids).
  3. History of type 1 diabetes mellitus, or uncontrolled type 2 diabetes mellitus (defined as [HbA1c] >8% at Screening)
  4. History of lymphoma, leukemia, or any active within the past 2 years (except for basal cell or squamous cell carcinomas of the skin or cervical carcinoma in situ that have been resected and with no evidence of disease).
  5. Active hepatobiliary disease.
  6. Documented history of heart failure ( Class III/IV) or a major adverse cardiac event within 12 weeks prior to Screening.
  7. Has a physical, medical, or psychological condition, that in the opinion of the Investigator, may interfere with the evaluation the study.
  8. The patient has a history of alcohol or illicit drug use disorder within 1 year prior to Screening.
  9. Had a prior organ transplant or stem cell transplant, with the exception of corneal transplant.
  10. Positive screening assessment for viral surface antigen, or anti- virus (HCV) antibody AND positive HCV RNA, or 1 and 2.
  11. Serum potassium levels >5.5 mmol/L at Screening.
  12. (ALT) and aspartate aminotransferase (AST) >2 × (ULN) at Screening.
  13. Treatment with non-steroid agents including biological drugs (e.g. rituximab), calcineurin inhibitors, cyclophosphamide, azathioprine, or mycophenolate mofetil within 12 weeks prior to Screening.
  14. History of serious side effects or allergic response to an angiotensin II antagonist or has a known sensitivity to any components in the IP.
  15. Unable to swallow oral medication.
  16. Prior participation in any Dimerix-sponsored DMX-200 clinical study.
  17. Participation in a clinical study with an product (IP) within 28 days or 5 half-lives (whichever is longer) prior to Screening or plans to participate in another study during the course of this study.
  18. Are study site personnel directly affiliated with this study and their immediate families

OLE PERIOD

Inclusion Criteria:

  1. A patient or parent/legal guardian (as appropriate) who is capable of giving signed informed consent, and where required, the patient is capable of providing assent.
  2. Patients who have completed participation in the double-blind period, including the Week 104 visit, and who may derive benefit from (continued) treatment with DMX-200, and/or continued follow-up
  3. The patient received blinded Investigational Product throughout the duration of the double-blind period up to the Week 104 visit
  4. The patient continues to meet the contraceptive requirements

Exclusion Criteria:

  1. The patient has met the criteria for permanent IP discontinuation or study discontinuation
  2. Any safety concerns identified during the double-blind period which, in the Investigator's opinion, may interfere with the patient's continued participation during the OLE period.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
286 participants (estimated)

Study arms

  • Experimental
    DMX-200 (repagermanium)

    Patients will receive 120 mg immediate release capsules of DMX-200 twice daily during the treatment period (104 weeks) OLE: Patients will receive 120 mg immediate release capsules of DMX-200 twice daily during the OLE period (108-212 weeks)

    Drug: DMX-200

  • Placebo comparator
    Placebo

    Patients will receive 120 mg immediate release capsules of Placebo twice daily

    Drug: Placebo

Interventions

  • DrugPropagermaniumStudies of PropagermaniumPropagermanium pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor.

    Also known as: Repagermanium

  • DrugPlacebo

    Patients will receive 120 mg capsules of Placebo twice daily

06

What researchers measure

Primary outcomes

  1. Evaluate the efficacy of DMX-200 in terms of urine protein/creatinine ratio (PCR) in patients with FSGS who are receiving an ARB.

    Percent change in urine PCR (based on 24-hour urine collection)

    Time frame: Baseline to Week 35

  2. Evaluate the efficacy of DMX-200 in terms of estimated glomerular filtration rate (eGFR) slope in patients with FSGS who are receiving an ARB (Analysis at week 35 and Week 104).

    Slope of eGFR

    Time frame: Baseline to Week 104

  3. OLE - Assess the long-term safety and tolerability of open-label treatment with DMX-200 in patients with FSGS who are receiving an ARB.

    Incidence and severity of treatment-related adverse events (AEs) and any adverse events of special interest (AESIs) and serious adverse events (SAEs) following long-term treatment with DMX-200.

    Time frame: Double-blind baseline to Week 216

Secondary outcomes

  1. Evaluate the incidence and severity of AEs with treatment of DMX-200 in adult and adolescent patients with FSGS who are receiving an ARB.

    Incidence and severity of AEs and clinically significant changes following treatment with DMX-200 compared with placebo.

    Time frame: Baseline to Week 104

  2. To evaluate the effect of DMX-200 on kidney function parameters including proteinuria in patients with FSGS who are receiving an ARB.

    Proportion of responders and non-responders following treatment with DMX-200 compared with placebo. Proportion of patients on treatment with DMX-200 compared with placebo that meet a composite endpoint of worsening in kidney function.

    Time frame: Baseline to Week 104

  3. OLE - Assess the long-term efficacy of open-label treatment with DMX-200 in patients with FSGS who are receiving an ARB.

    Slope of eGFR and percent change in urine PCR

    Time frame: From Week 108 (Baseline) at each visit

  4. OLE - Evaluate the long-term effect of open-label treatment with DMX-200 on kidney function parameters in patients with FSGS who are receiving an ARB.

    Proportion of patients on treatment with DMX-200 that meet a composite endpoint of worsening in kidney function.

    Time frame: Double blind baseline to Week 216

07

Study locations

28 of 220 sites recruiting
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
    Recruiting
  • Arizona Kidney Disease and Hypertension Center
    Phoenix, Arizona 85027, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Loma Linda University Medical Center
    Loma Linda, California 92354, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
    Recruiting
  • University of California, Los Angeles
    Los Angeles, California 90095, United States
    Recruiting
  • Amicis Research Centre
    Northridge, California 91324, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Northridge Clinical Research Inc.
    Northridge, California 91324, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Kaiser Permanente
    Oakland, California 94612, United States
    Recruiting
  • University of California Davis Health System
    Sacramento, California 95817, United States
    Recruiting
  • Scripps Health
    San Diego, California 92103, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Stanford Hospital and Clinic
    Stanford, California 94305, United States
    Recruiting
  • University of Colorado Anschutz Medical Campus
    Denver, Colorado 80204, United States
    Recruiting
  • Denver Nephrology Research Division
    Denver, Colorado 80230, United States
    Recruiting
  • South Florida Nephrology Group, P.A.
    Coral Springs, Florida 33071, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Nicklaus Children's Hospital
    Miami, Florida 33155, United States
    Recruiting
  • CTR Oakwater LLC
    Orlando, Florida 32806, United States
    Recruiting
  • Emory University School of Medicine
    Atlanta, Georgia 30307, United States
    Recruiting
  • Georgia Nephrology
    Lawrenceville, Georgia 30046, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Boise Kidney
    Boise, Idaho 83706, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CARE Institute - Idaho Falls
    Idaho Falls, Idaho 83404, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University of Chicago
    Chicago, Illinois 60637, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • NorthShore University HealthSystem
    Evanston, Illinois 60201, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Nephrology Associates of Northern Illinois and Indiana (NANI Research)
    Oak Brook, Illinois 60523, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University of Louisville
    Louisville, Kentucky 40202, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • The Johns Hopkins Hospital
    Baltimore, Maryland 21205, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University of Michigan
    Ann Arbor, Michigan 48109, United States
    Recruiting
  • Intermed Consultants
    Edina, Minnesota 55435, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
    Recruiting
  • CARE Institute - Nephrology & Hypertension Associates
    Tupelo, Mississippi 38801, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Children's Mercy Research Institute
    Kansas City, Missouri 64111, United States
    Recruiting
  • Washington University, School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
  • Somnos Clinical Research
    Lincoln, Nebraska 68510, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
    Recruiting
  • Renal Medicine Associates
    Albuquerque, New Mexico 87109, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
    Recruiting
  • University of North Carolina
    Chapel Hill, North Carolina 27599, United States
    Recruiting
  • Atrium Health
    Charlotte, North Carolina 28105, United States
    Recruiting
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Ohio State University
    Columbus, Ohio 43210, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Kidney and Hypertension Center
    Roseburg, Oregon 97471, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • The Childrens Hospital of Philadelphia Kohls GI Nutrition and Diagnostic Center
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • South Carolina Clinical Research
    North Charleston, South Carolina 29406, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Carolina Nephrology, PA
    Spartanburg, South Carolina 29306, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Arlington Nephrology
    Arlington, Texas 76015, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Nephrotex Research Group
    Dallas, Texas 75231, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Renal Disease Research Institute, LLC - Dallas
    Dallas, Texas 75235, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • MedResearch, Inc
    El Paso, Texas 79902, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University Texas Medical Branch
    Galveston, Texas 77555, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Kaleidoscope Clinical Research
    Houston, Texas 77054, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Clear Lake Specialties
    Webster, Texas 77598, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Utah Kidney Research Institute
    Salt Lake City, Utah 84115, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centro Medico Dra Laura Maffei Investigacion Clinica Aplicada
    Buenos Aires, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Italiano de Buenos Aires
    Buenos Aires, Argentina
    Recruiting
  • Organizacion Medica de Investigacion (OMI)
    CABA, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centro Médico de Nutrición y Diabetes-CENUDIAB
    Ciudad Autonoma Buenos Aires, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Britanico de Buenos Aires
    Ciudad Autonoma Buenos Aires, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital General de Agudos Dr. Cosme Argerich
    Ciudad Autonoma Buenos Aires, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Clinica Privada Velez Sarsfield
    Córdoba, Argentina
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Clinica de Nefrologia Urologia y Enf. Cardiovasculares S.A.
    Santa Fe, Argentina
    Recruiting
  • Griffith University
    Brisbane, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Princess Alexandra Hospital
    Brisbane, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Austin Hospital
    Melbourne, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Monash Health
    Melbourne, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • St Vincent's Hospital Melbourne
    Melbourne, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Western Health
    Melbourne, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • John Hunter Hospital
    Sydney, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Liverpool Hospital
    Sydney, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Nepean Hospital
    Sydney, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Royal North Shore Hospital
    Sydney, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu
    Botucatu, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital das Clínicas da Universidade Federal de Pernambuco
    Recife, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • HUPE-UERJ - Hospital Universitário Pedro Ernesto - Universidade Estadual do Rio de Janeiro
    Rio de Janeiro, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Fundação Oswaldo Ramos - Hospital do Rim
    São Paulo, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital das Clínicas da Faculdade de Medicina da USP
    São Paulo, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • The First Affiliated Hospital of Baotou Medical College
    Baotou, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Beijing Anzhen Hospital, Capital Medical University
    Beijing, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Beijing Tongren Hospital, Capital Medical University
    Beijing, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Peking University First Hospital
    Beijing, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Peking University People's Hospital
    Beijing, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Sichuan Provincial People's Hospital
    Chengdu, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • West China Hospital, Sichuan University
    Chengdu, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Guangdong Provincial People's Hospital
    Guangzhou, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • The First Affiliated Hospital of Zhejiang University school of medicine
    Hangzhou, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Zhejiang Provincial People's Hospital
    Hangzhou, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • The Affiliated Hospital of Inner Mongolia Medical University
    Hohhot, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Shandong Provincial Hospital
    Jinan, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • The First Affiliated Hospital of Nanchang University
    Nanchang, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Jiangsu Province Hospital
    Nanjing, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Ruijin Hospital of Shanghai Jiaotong University School of Medicine
    Shanghai, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Peking University Shenzhen Hospital
    Shenzhen, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Tianjin Medical University General Hospital
    Tianjin, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • General Hospital of Ningxia Medical University
    Yinchuan, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Affiliated Hospital of Guangdong Medical University
    Zhanjiang, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Všeobecná fakultní nemocnice v Praze
    Prague, Czechia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Rigshospitalet
    Copenhagen, Denmark
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Kolding Sygehus
    Kolding, Denmark
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Odense University Hospital
    Odense, Denmark
    Active, not recruiting

    Not enrolling at this site — choose another above.

Showing the first 100 of 220 sites across 21 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2022 (actual). Primary completion is estimated for Dec 2029, 91 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2021
First posted
Jan 10, 2022
StartActual
May 30, 2022
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2029
Last update
Feb 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05183646
Lead sponsor
Dimerix Bioscience Pty Ltd
Responsible party
Sponsor
First posted
Jan 10, 2022
Start date
May 30, 2022
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Feb 3, 2026

Study contacts

David Fuller
Contact
ACTION3@dimerix.com
+61 1300 813 321
Alisha Smith
Contact
ACTION3@dimerix.com
+61 1300 813 321
David Fuller
study director · Dimerix Bioscience Pty Ltd

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Propagermanium

Start the discussion